ReWalk Robotics (LFWD) & Its Rivals Head-To-Head Review

ReWalk Robotics (NASDAQ:LFWDGet Free Report) is one of 49 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its competitors? We will compare ReWalk Robotics to related businesses based on the strength of its dividends, institutional ownership, earnings, valuation, analyst recommendations, profitability and risk.

Insider & Institutional Ownership

3.6% of ReWalk Robotics shares are held by institutional investors. Comparatively, 44.4% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 2.1% of ReWalk Robotics shares are held by insiders. Comparatively, 9.2% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

ReWalk Robotics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, ReWalk Robotics’ competitors have a beta of 0.91, meaning that their average stock price is 9% less volatile than the S&P 500.


This table compares ReWalk Robotics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ReWalk Robotics -159.76% -28.19% -23.29%
ReWalk Robotics Competitors -70.30% -67.30% -15.03%

Analyst Recommendations

This is a summary of recent ratings for ReWalk Robotics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ReWalk Robotics 0 0 1 0 3.00
ReWalk Robotics Competitors 339 1173 2277 98 2.55

ReWalk Robotics presently has a consensus price target of $21.00, suggesting a potential upside of 272.34%. As a group, “Surgical appliances & supplies” companies have a potential upside of 6.57%. Given ReWalk Robotics’ stronger consensus rating and higher probable upside, equities analysts plainly believe ReWalk Robotics is more favorable than its competitors.

Earnings and Valuation

This table compares ReWalk Robotics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ReWalk Robotics $13.85 million -$22.13 million -1.97
ReWalk Robotics Competitors $1.45 billion $152.74 million 25.06

ReWalk Robotics’ competitors have higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


ReWalk Robotics competitors beat ReWalk Robotics on 8 of the 13 factors compared.

About ReWalk Robotics

(Get Free Report)

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with's FREE daily email newsletter.